作者
Astha Thakkar, Jesus D Gonzalez-Lugo, Niyati Goradia, Radhika Gali, Lauren C Shapiro, Kith Pradhan, Shafia Rahman, So Yeon Kim, Brian Ko, R Alejandro Sica, Noah Kornblum, Lizamarie Bachier-Rodriguez, Margaret McCort, Sanjay Goel, Roman Perez-Soler, Stuart Packer, Joseph Sparano, Benjamin Gartrell, Della Makower, Yitz D Goldstein, Lucia Wolgast, Amit Verma, Balazs Halmos
发表日期
2021/8/9
期刊
Cancer cell
卷号
39
期号
8
页码范围
1081-1090. e2
出版商
Elsevier
简介
As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed …
学术搜索中的文章
A Thakkar, JD Gonzalez-Lugo, N Goradia, R Gali… - Cancer cell, 2021